LABT Lakewood-Amedex Biotherapeutics Inc. - Common Stock
$2.17
Price · Aug 19, 2026
Fundamentals as of Aug 14, 2026
52W Range
$0–$10
19% of range
Analyst Rating
—
Price Target
$12
+453% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
LABT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$2.17
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $10
LABT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
LABT
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
LABT
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
LABT
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
LABT
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
LABT
Peer Median
LABT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
1 analysts · 2026-08-19
Low
$12.00
High
$12.00
Median target
$12.00
+453.0%
Mean target
$12.00
+453.0%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| LABT | — | — | — | — | — | — |
| XBIO | — | -1.4 | 19.0% | — | — | — |
| PMCB | $8M | -0.3 | — | — | -56.7% | — |
| BRTX | $10M | -0.7 | -10.3% | -3959.4% | -547.6% | 93.4% |
| BCAB | — | -0.6 | — | — | — | — |
| APVO | $9M | -0.1 | — | — | -217.2% | — |
| TCRT | — | -1.5 | -50.0% | — | — | — |
| SILO | $5M | -0.7 | 0.00% | -5863.5% | -75.3% | 38.6% |
| REVB | — | — | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Balance Sheet 17
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $236.4K | |
| Prepaid Expense | $69.0K | |
| Current Assets | $305.4K | |
| PP&E (Net) | $9.2K | |
| Other Non-current Assets | $8.1K | |
| Total Assets | $481.6K | |
| Accounts Payable | $381.0K | |
| Current Liabilities | $2M | |
| Capital Leases | $41.0K | |
| Total Liabilities | $2M | |
| Common Stock | $70 | |
| Paid-in Capital | $52M | |
| Retained Earnings | $-53M | |
| Treasury Stock | $150.0K | |
| Stockholders' Equity | $-2M | |
| Liabilities + Equity | $481.6K | |
| Shares Outstanding | 699,648 |
Income Statement 13
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Cost of Revenue | · | $507.3K | |
| R&D Expense | $503.0K | $182.1K | |
| SG&A Expense | $3M | $703.4K | |
| Operating Expenses | $4M | $886.8K | |
| Operating Income | $-4M | $-886.8K | |
| Interest Income | $28.3K | $1.1K | |
| Other Non-op | $17.7K | $-36.5K | |
| Net Income | $-4M | $-923.3K | |
| EPS (Basic) | $-2.75 | $-0.20 | |
| EPS (Diluted) | $-2.75 | $-0.20 | |
| Shares (Basic) | 1,419,767 | 6,995,469 | |
| Shares (Diluted) | 1,419,767 | 6,995,469 | |
| EBITDA | $-4M | $-886.8K |
Balance Sheet 18
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Cash & Equivalents | $3M | $11.7K | |
| Short-term Investments | $2M | · | |
| Prepaid Expense | $256.0K | $38.9K | |
| Current Assets | $5M | $50.6K | |
| PP&E (Net) | $6.9K | $8.1K | |
| Other Non-current Assets | $7.8K | $8.1K | |
| Total Assets | $5M | $196.3K | |
| Accounts Payable | $165.9K | $547.8K | |
| Current Liabilities | $628.9K | $3M | |
| Capital Leases | · | $10.3K | |
| Total Liabilities | $628.9K | $3M | |
| Common Stock | $217 | $704 | |
| Paid-in Capital | $73M | $52M | |
| Retained Earnings | $-69M | $-54M | |
| Treasury Stock | $150.0K | $150.0K | |
| Stockholders' Equity | $4M | $-3M | |
| Liabilities + Equity | $5M | $196.3K | |
| Shares Outstanding | 2,169,199 | 7,043,330 |
Cash Flow 3
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Stock-based Comp | $61.2K | $46.2K | |
| Operating Cash Flow | $-2M | $-349.7K | |
| Financing Cash Flow | $7M | $125.0K |
Profitability 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| ROA | -152.1% | -940.5% | |
| ROE | -174.2% | 65.0% |
Liquidity & Solvency 2
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Current Ratio | 7.7 | 0.0 | |
| Quick Ratio | 7.3 | 0.0 |
Valuation (TTM) 3
| Metric | Trend | Q2 2026 | Q1 2026 |
|---|---|---|---|
| Market Cap | $7M | · | |
| P/B | 1.6 | · | |
| P / Tangible Book | 1.6 | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Company insiders 1 insider · 0 officers · 1 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Joseph Edward Tucker | Director | April 24, 2026 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only